Pharmafile Logo
Pharmafocus logo
Advanced Search

guselkumab

Showing 5 posts of 5 posts found.

bowel_cancer_screening

European Commission approves Johnson & Johnson’s Crohn’s disease therapy

May 12, 2025
Market Access, Research and Development, Sales and Marketing Crohn’s disease, European Commission, Gastrointestinal tract, Johnson & Johnson, guselkumab, marketing authorisation

The European Commission (EC) has granted Marketing Authorisation (MA) to Johnson & Johnson’s Tremfya (guselkumab) for the treatment of moderately …

News
janssen_latest_logo_on_sign_closer

Janssen reveals positive CHMP opinion, long-term data for psoriasis drug guselkumab

September 19, 2017
Manufacturing and Production, Research and Development, Sales and Marketing EMA< CHMP, Janssen, guselkumab, pharma, pharmaceuticals

Janssen has announced that its psoriasis drug guselkumab has been awarded a positive opinion by the EMA’s Committee for Medicinal …

News
janssen_latest_logo_on_sign_closer

Phase 3 data for Janssen psoriasis drug shows efficacy over Humira

March 6, 2017
Research and Development, Sales and Marketing Humira, Janssen, guselkumab, psoriasis

Janssen has revealed new Phase 3 data for its human monoclonal antibody guselkumab in the treatment of adults with moderate …

News
jj_2johnson_and_johnson

J&J’s IL-23 drug guselkumab outstrips the competition in Phase III trial

October 3, 2016
Research and Development, Sales and Marketing AbbVie, Humira, Johnson & Johnson, guselkumab

Johnson & Johnson’s IL-23 drug guselkumab proved to be more effective at clearing moderate to severe cases of the plaque …

News
Janssen image

Janssen psoriasis drug beats placebo

March 25, 2014
Research and Development, Sales and Marketing Janssen, dermatology, guselkumab

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025